Advertisement
Organisation › Details
Quercis Pharma (Group)
Quercis Pharma AG is a private, biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is advancing a development pipeline of late-stage clinical studies that focus on the prevention of venous thromboembolism (VTE) in cancer patients. In addition, Quercis targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola and COVID-19. The Company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis plans to initiate two Phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue U.S. Food and Drug Administration approval for the prevention of VTE in all cancer types based on these studies. In addition, the Company is preparing to conduct a number of studies for the treatment of SCD (Phase 2) and COVID-19 (Phase 2/3). *
Start | 2019-01-01 reorganised | |
Today | Quercis Pharma AG | |
Industry | anticoagulant | |
Industry 2 | drug development | |
Person | Boghossian, John (Quercis Pharma 202104– CEO before VP of Operations at Compass Pathways + Boston Consulting) | |
Person 2 | Veraart, Manon (Quercis Pharma 202104– CBO before Compass Pathways + Boston Consulting + Goldman Sachs) | |
Region | Zug ZG | |
Country | Switzerland | |
Street | 5 Nordstr. | |
City | 6300 Zug ZG | |
Address record changed: 2023-07-10 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Quercis Pharma AG. (4/13/21). "Press Release: Quercis Announces Executive Leadership Appointments". Zug. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Quercis Pharma (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top